Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin glulisine, insulin lispro, insulin glargine, NPH insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 138
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more

Conditions: Diabetes Mellitus
Interventions: Insulin Lispro, Exubera; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 62
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine, LY2189265, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 36
States / cities: Concord, California • La Mesa, California • Lancaster, California + 33 more

Conditions: Type 2 Diabetes
Interventions: Lispro mix 75/25, Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions: Sitagliptin, glargine, lispro; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus
Interventions: Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject; Drug
Lead sponsor: Biodel; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 2 Diabetes
Interventions: Insulin Glargine, Metformin, Prandial insulin, Exenatide; Drug
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Diabetes in Pregnancy, Gestational Diabetes
Interventions: Insulin glargine alone, Insulin glargine + insulin lispro; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Glargine, LY2605541, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Concord, California • Escondido, California • Fresno, California + 9 more

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Glargine insulin, Lispro insulin, NPH Insulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Insulin Lispro (U100); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more

Conditions: Diabetes Mellitus, Type 2
Interventions: premeal insulin lispro mixtures, insulin glargine, metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin; Drug · Other · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Glargine insulin, NPH insulin and regular insulin, lispro insulin; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Search by objective public record fields.

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Oral Anti Diabetic Agents in the Hospital

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Linagliptin Inpatient Trial

Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)

A Study in Participants With Type 1 Diabetes Mellitus

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Insulin Therapy in the Hospital Comparing Two Protocols

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery